CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
acarbosedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02865499
NCT02865499Phase 2Completed
CompareCT.gov

Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects

The University of Texas Health Science Center at San Antonio·interventional·Posted Aug 12, 2016·Updated Mar 14, 2019

In Brief

A Phase 2 clinical trial evaluating acarbose for Aging. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans. It is a pilot study to: i) better estimate power for a larger trial, ii) establish the safety and potential beneficial effects of acarbose in non-diabetic elderly humans, and iii) determine whether the effects of acarbose on the microbiome likely play a role in its enhancement of longevity and/or healthy aging. These are essential initial steps for translating acarbose into an anti-aging human therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 12, 2016
Enrollment StartJun 1, 2016
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.9 years ago

Interventions

acarbosedrug

acarbose treatment with meals